Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 2, 2009, Pages 166-172

  Maher, Vincent M G ^a   Kitano, Yuri ^b   Neuwirth, Clare ^c   Davies, Graham J ^c   Maseri, Attilio ^d   Thompson, Gilbert R ^c   Andreotti, Felicita ^e  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b SUDA Clinic   (Japan)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Apheresis; Coronary artery disease; Dextran sulphate; Familial hypercholesterolaemia; PAI 1 antigen; PAI 1activity

Indexed keywords

APOLIPOPROTEIN B; DEXTRAN SULFATE; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; APHERESIS; ARTICLE; BINDING AFFINITY; CHOLESTEROL BLOOD LEVEL; CIRCADIAN RHYTHM; CLINICAL ARTICLE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; MALE; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN TARGETING; TREATMENT DURATION;

ADULT; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DEXTRAN SULFATE; FEMALE; HOMEOSTASIS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 67849133451     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0260-8     Document Type: Article

References (32)

1. Nilsson L, Banfi Diczfalusy U, Tremoli E, Hamsten A, Eriksson P (1998) Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 18(11):1679-1685
2. Wojta J, Nakamura T, Fabry A, Hufnagl P, Beckmann R, Mc Grath K et al (1994) Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells. Blood 84(1):151-157
3. Morange PE, Aubert J, Peiretti F, Lijnen HR, Vague P, Verdier M et al (1999) Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 48(4):890-895. doi: 10.2337/diabetes.48.4.890
4. Sprengers ED, Kluft C (1987) Plasminogen activator inhibitors. Blood 69:381-387
5. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA (1997) Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100(1):58-67. doi: 10.1172/JCI119521
6. Madoiwa S, Komatsu N, Mimuro J, Kimura K, Matsuda M, Sakata Y (1999) Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation. Blood 94(2):475-482
7. Sier CF, Verspaget HW, Griffioen G, Verheijen JH, Quax PH, Dooijewaard G et al (1991) Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology 101(6):1522-1528
8. Sasaki A, Kurisu A, Ohno M, Ikeda Y (2001) Overweight/obesity, smoking, and heavy alcohol consumption are important determinants of plasma PAI-1 levels in healthy men. Am J Med Sci 322(1):19-23. doi: 10.1097/ 00000441-200107000-00004
9. Lyon CJ, Hsueh WA (2003) Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 115(Suppl 8A):62S-68S. Review. doi: 10.1016/j.amjmed.2003.08.014
10. Devaraj S, Xu DY, Jialal I (2003) C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation 107(3):398-404. doi: 10.1161/ 01.CIR.0000052617.91920.FD
11. Barbash GI, Hod H, Roth A, Miller HI, Rath S, Harzahav Y (1989) Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 64:1231-1235. doi: 10.1016/ 0002-9149(89)90559-6
12. Hamsten A, Wiman B, de Faire U, Blomback M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557-1563
13. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landon C et al (1987) Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9. doi: 10.1016/ S0140-6736(87)93050-9
14. Nilsson JB, Boman K, Jansson JH, Nilsson T, Naslund U (2007) The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase. J Thromb Thrombolysis. doi: 10.1007/s11239-007-0086-9
15. Juhan-Vague I, Alessi MC, Vague P (1991) Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462. doi: 10.1007/BF00403280
16. Ley CJ, Swan J, Godsland IF, Walton C, Crook D, Stevenson JC (1994) Insulin resistance, lipoproteins, body fat and hemostasis in non-obese men with angina and a normal or abnormal angiogram. J Am Coll Cardiol 23:377-383
17. Chen CH, Eng HL, Chang CJ, Tsai TT, Lai ML, Chen HY et al (2003) 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med 142(2):100-105. doi: 10.1016/S0022-2143(03)00063-5
18. Sundell IB, Dahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK (1990) Reduction of elevated plasminogen activator inhibitor activity in sedentary men. Fibrinolysis 4:97-98. doi: 10.1016/0268-9499(90)90115-Z
19. Gris JC, Schved JF, Aguilar-Martinez P, Arnaud A, Sanchez N (1990) Impact of physical training on plasminogen activator inhibitor activity in sedentary men. Fibrinolysis 4:97-98. doi: 10.1016/0268-9499(90)90375-T
20. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J (1987) Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 57:326-328
21. Mehrabian M, Peter JB, Barnard RJ, Lusis AJ (1990) Dietary regulation of fibrinolytic factors. Atherosclerosis 84:25-32. doi: 10.1016/ 0021-9150(90)90004-3
22. Rupin A, Gaertner R, Mennecier P, Richard I, Benoist A, De Nanteuil G (2008) S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood. Thromb Res 122:265-270
23. Preissner KT, Holzhutter S, Justus C, Muller-Berghaus G (1989) Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 74(6):1989-1996
24. Mabuchi H, Michishita I, Takeda M, Fujita H, Koizumi J, Takeda R et al (1987) A new low density lipoprotein apheresis system using two dextran sulphate cellulose columns in an automated column regenerating unit (LDL continuous aphereis). Atherosclerosis 68:19-26. doi: 10.1016/ 0021-9150(87)90089-X
25. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB et al (1995) The Familial Hypercholesterolaeima Regression Study. A randomised comparison of bi-weekly LDL apheresis plus Simvastatin versus Colestipol plus Simvastatin. Lancet 345:811-816. doi: 10.1016/ S0140-6736(95)92961-4
26. Friedewald WT et al (1972) Estimation of the concentrations of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499
27. Andreotti F, Kluft C, Davies GJ, Huisman LGm, De Bart ACW, Maseri A (1991) Effects of propranolol (long-acting) on the circadian fluctuation of tissue-type plasminogen activator and plasminogen activator inhibitor-1. Am J Cardiol 68:1295-1299. doi: 10.1016/0002-9149(91)90234-C
28. DiMinno G, Cerbrone AM, Cirillo F, Postglione A, Colucci M, Semeraro N et al (1990) Haemostasis variables in homozygous familial hypercholesterolaemia. Effect of regular plasma cholesterol removal by low-density lipoprotein apheresis. Arteriosclerosis 10:1119-1126
29. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT (1998) Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 191(7):2305-2312
30. Welty FK, Mittleman MA, Wilson PW, Sutherland PA, Matheney TH, Lipinska I et al (1997) Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. Circulation 96(10):3811-3812
31. Fay WP, Shapiro AD, Shih JL, Schleef RRR, Ginsburg D (1992) Human plasminogen activator inhibitor-1 deficiency. Circulation Suppl 86:I-149-596
32. Izuhara Y, Takahashi S, Nangaku M, Takizawa S, Ishida H, Kurokawa K, van Ypersele de Strihou C, Hirayama N, Miyata T (2008) Inhibition of plasminogen activator inhibitor-1: Its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 28(4):672-677. doi: 10.1161/ATVBAHA.107.157479